MDMA-Assisted Psychotherapy for PTSD: New Australian Guidelines Released for Public Consultation
Australia continues to lead the way in innovative mental health treatment, having become the first nation in 2023 to reschedule MDMA - commonly known as ecstasy - for therapeutic use.This pivotal change moved MDMA from a prohibited substance (Schedule 9) to a controlled substance (Schedule 8), allowing authorized psychiatrists to administer it within a carefully controlled clinical setting for the treatment of Post-Traumatic Stress Disorder (PTSD). Now, a crucial next step has been taken: the release of a new Australian clinical practice guideline designed to ensure the safe and effective implementation of MDMA-assisted psychotherapy (MDMA-AP).
This draft guideline, currently open for public consultation, represents a significant effort to provide clinicians and individuals living with PTSD with the information needed to make informed decisions about this emerging treatment option. Developed by the Center for Medicine Use and Safety (CMUS) and the Neuromedicines Revelation Centre at Monash University, the guideline isn’t simply a set of rules, but a carefully considered framework built on rigorous evidence and a deep understanding of the complexities of PTSD.
A Collaborative Approach to Guideline Progress
The development of this guideline was a truly collaborative undertaking. A Guideline Development Group of 18 experts – encompassing disciplines from general practice and health economics to law, lived experience, and neuroscience – meticulously reviewed the available evidence. Further bolstering the guideline’s credibility, a 21-person Expert Group, including clinicians and patients with direct experience in MDMA-AP, provided invaluable insights. crucially, the process also involved engagement with 17 stakeholder organizations, including professional societies, government agencies, and consumer groups.This broad consultation ensures the guideline reflects a holistic viewpoint,considering not only clinical efficacy but also patient values,resource availability,equity,and practical feasibility. As Professor Simon bell, CMUS Director and Guideline Clinical Chair, explains, “The Guideline is based on consideration of benefits and harms, certainty of the evidence, patient values and preferences, resources, equity, acceptability and feasibility.”
What Does the Guideline Recommend?
While acknowledging the potential benefits of MDMA-AP, the draft guideline currently offers a conditional recommendation against its routine use for PTSD. This cautious approach reflects the need for further research and a thorough understanding of the treatment’s long-term effects. Though, the guideline outlines specific circumstances where MDMA-AP may be considered.Specifically, the draft guideline recommends MDMA-AP be limited to:
Adults (18 years or older): The treatment is not currently recommended for individuals under 18.
Persistent PTSD Symptoms: Individuals must have experienced PTSD symptoms for at least six months following diagnosis.
moderate to Severe Symptoms: Symptoms must be moderate or severe in the month preceding treatment consideration.
Prior Evidence-Based Treatment: Patients should have already undergone an adequate trial of first-line, evidence-based treatments for PTSD (such as traditional psychotherapy and medication) without significant enhancement.
Low Risk of Re-Traumatization: Careful assessment is needed to ensure the treatment environment minimizes the risk of triggering re-exposure to trauma.
Addressing a Significant Unmet Need
The development of these guidelines is especially timely. As Dr. Alene Yong, Project Manager at CMUS, points out, “Nearly half of people with PTSD do not improve with current treatments.” Considering that the Australian Institute of Health and Welfare estimates up to 11% of Australians will experience PTSD in thier lifetime, this represents a substantial unmet need. MDMA-AP offers a potential avenue for those who haven’t found relief thru conventional methods, but its implementation requires careful consideration and adherence to best practices.
What’s Included in the Draft Guideline?
The extensive draft guideline includes:
Four Recommendations for Clinical Practice: These outline the core principles for determining appropriate patient selection and treatment protocols.
18 Good Practice Statements: Providing detailed guidance on the practical aspects of delivering MDMA-AP, from preparation and session conduct to post-treatment integration.
11 recommendations for Future Research: Highlighting areas where further investigation is needed to refine our understanding of MDMA-AP and optimize its effectiveness.
Have Your Say: Public Consultation is Now Open
The draft guideline is currently available for public consultation on the MAGICapp platform ([https://app.magicapp.org/#/guideline/Ee438n](https://app.magicapp.org/#/guideline
![Coastal Retreat: Climate Change Forces Settlements to Move | [Year] Update](https://i0.wp.com/www.futurity.org/wp/wp-content/uploads/2025/12/climate-change-coastal-settlements-1600.jpg?resize=330%2C220&ssl=1 "Coastal Retreat: Climate Change Forces Settlements to Move | [Year] Update")
